Table 1 Sample characteristics of the combined 1H-MRS and cognition cohort.
n = 85 | |
|---|---|
Sex male/female | 71/14 |
Age (years) | 29.47 ± 8.29 |
Age of onset (years) | 24.44 ± 6.47 |
Duration of illness (years) | 4.83 ± 6.30 |
Diagnosis psychosis unspecified/schizophrenia/delusional disorder | 21/63/1 |
Ethnicity White/Black/Mixed White Black/Asian/Other | 44/22/5/7/7 |
Benzodiazepine yes/no | Aug-77 |
Antidepressant yes/no | 13/72 |
Current smoking no/less than daily/daily | 35/5/45 |
Current cannabis yes/no | Oct-75 |
CPZE dose (mg/day) | 456.54 ± 298.39 |
Current antipsychotic | |
Amisulpride | 6 |
Aripiprazole | 18 |
Clopixol | 3 |
Paliperidol | 4 |
Haloperidol | 1 |
Flupenthixol | 2 |
Olanzapine | 20 |
Quetiapine | 11 |
Risperidone | 13 |
Combination | 7 |
Symptom severity | |
PANSS total | 68.92 ± 18.6 |
PANSS positive | 16.88 ± 6.16 |
PANSS negative | 17.24 ± 5.61 |
PANSS general | 34.80 ± 9.15 |
Cognition | |
Verbal memory | 39.41 ± 11.10 |
Verbal fluency | 31.53 ± 9.10 |
Working memory | 18.31 ± 4.33 |
Attention & information processing speed | 47.25 ± 11.17 |
Motor speed* | 67.82 ± 14.67 |
Executive function | 16.42 ± 4.07 |
BACS-t* | 31.41 ± 13.04 |
BACS-z* | −1.84 ± 1.32 |
Glutamate neurometabolites | |
ACC Glucorr (total, n = 85) | −0.01 ± 0.97 |
CU (n = 8) | 13.07 ± 1.97 |
UoE (n = 12) | 14.17 ± 3.37 |
UoM (n = 31) | 15.22 ± 4.14 |
KCL (n = 34) | 17.52 ± 3.85 |
CRLB | 5.82 (0.88) |
ACC Glxcorr (total, n = 85) | −0.01 ± 0.98 |
CU (n = 8) | 17.44 ± 3.21 |
UoE (n = 12) | 20.76 ± 4.61 |
UoM (n = 31) | 21.70 ± 5.87) |
KCL (n = 34) | 23.12 ± 4.46) |
CRLB | 6.18 (1.36) |
